Brief: Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara Biotherapeutics

16/01/2025 13:36

Jan 16 (Reuters) - Atara Biotherapeutics Inc  ATRA.O :
    * ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS
UPDATE ON
EBVALLOTM (TABELECLEUCEL)
    * ATARA BIOTHERAPEUTICS INC: RECEIVED FDA COMPLETE RESPONSE
LETTER
(CRL) SOLELY RELATED TO INSPECTION FINDINGS AT THIRD-PARTY
MANUFACTURER
    * ATARA BIOTHERAPEUTICS INC: CRL DID NOT IDENTIFY
DEFICIENCIES
RELATED TO CLINICAL EFFICACY OR SAFETY DATA IN BLA
    * ATARA BIOTHERAPEUTICS INC: ENGAGED ADVISOR TO SUPPORT
EXPLORATION OF ALL STRATEGIC OPTIONS
    * ATARA BIOTHERAPEUTICS: GOT INTO NON-BINDING TERM SHEET
WITH
REDMILE GROUP TO PROVIDE UP TO $15 MILLION IN FUNDING
    * ATARA BIOTHERAPEUTICS: INTENDS TO SUSPEND ALL CAR-T
ACTIVITIES,
SIGNIFICANTLY CUT EXPENSES IF RESOLUTION NOT REACHED FOR FUNDING
FOR PROGRAMS IN Q1

Source text:  ID:nBw4SHWVza 
Further company coverage:  ATRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))